Article Text

Download PDFPDF
Rheumatology and palliative care: needs and opportunities
  1. Kwok Ying Chan1,
  2. Desmond Y H Yap2,
  3. Ho Yin Chung3,
  4. Tak Mao Chan2,
  5. Harinder Singh Harry Gill4 and
  6. Chak Sing Lau3
  1. 1 Palliative Medical Unit, Grantham Hospital, Hong Kong, Hong Kong
  2. 2 Division of Nephrology, Department of medicine, The University of Hong Kong, Hong Kong, Hong Kong
  3. 3 Division of Rheumatology and Clinical Immunology, Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
  4. 4 Division of Haematology, Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
  1. Correspondence to Dr Kwok Ying Chan, Palliative Medical Unit, Grantham Hospital, 125 Wong Chuk Hang Road, Aberdeen, Hong Kong; cky842{at}yahoo.com.hk

Abstract

Palliative care (PC) has expanded to medical conditions beyond its conventional scope of terminal malignancy and end-stage organ failure. This editorial showed our opinion in care model for the integration of PC into rheumatology and the growing needs of both rheumatology and PC services in view of increasing comorbidities and novel therapies. We anticipate an escalating demand for PC in this special group of patients who have concomitant long-standing systemic rheumatic diseases and age-related comorbidities. In addition, patients with advanced malignancy who develop rheumatological problems and require PC is also an emerging area of service need.

  • Rheumatology
  • Pain
  • Psychological care

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors KYC, DYHY and HYC: draft writing, topic proposal and draft structuring. TMC, HSHG and CSL: draft writing and draft structuring.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.